EQS-Adhoc
COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A. PUBLISH DEFINITIVE FINAL RESULTS OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES OF CASSIOPEA S.P.A. - Seite 2
About Cassiopea
Cassiopea is a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential
dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been
largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to
optimize the commercial potential for its products directly or with partners. For further information on Cassiopea, please visit www.cassiopea.com.
Contact |
Diana Harbort, CEO & Head of Investor Relations Cassiopea S.p.A. Tel: +39 02 868 911 24, dharbort@cassiopea.com |
Lesen Sie auch
Disclaimer
This communication (the "Communication") has been prepared by Cosmo Pharmaceuticals N.V. ('Cosmo" and together with its subsidiaries, "we", "us" or the "Group") solely for informational purposes and has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of any of the Group. Cosmo reserves the right to amend or replace the Communication at any time, and undertakes no obligation to provide the recipients with access to any additional information. Cosmo shall not be obligated to update or correct the information set forth in the Communication or to provide any additional information. Nothing in this Presentation is, or should be relied upon as, a promise or representation as to the future.